Literature DB >> 16967301

Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection.

Jean Klastersky1, Marianne Paesmans.   

Abstract

RATIONALE: Invasive fungal infections, especially aspergillosis, are a major problem in patients who undergo aggressive therapy for haematological malignancies. Presently, the standard therapy for demonstrated aspergillar infection is voriconazole. Because the morbidity and the mortality of proven aspergillar infection is relatively high, empirical and preemptive approaches have been explored.
FINDINGS: Empirical therapy is effective at the cost of overtreatment in a significant number of patients. This can be reduced through the preemptive approach; however, its equivalence in terms of successful therapy and mortality should be studied further and, optimally, in prospective controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16967301     DOI: 10.1007/s00520-006-0137-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  28 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Decisions about voriconazole versus liposomal amphotericin B.

Authors:  Thomas J Walsh; Jeannette Lee; William E Dismukes
Journal:  N Engl J Med       Date:  2002-05-09       Impact factor: 91.245

3.  Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?

Authors:  Jean Klastersky
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

Review 4.  The changing face of invasive fungal infections in hematopoietic cell transplant recipients.

Authors:  John R Wingard
Journal:  Curr Opin Oncol       Date:  2005-03       Impact factor: 3.645

5.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Authors:  Thomas J Walsh; Peter Pappas; Drew J Winston; Hillard M Lazarus; Finn Petersen; John Raffalli; Saul Yanovich; Patrick Stiff; Richard Greenberg; Gerald Donowitz; Mindy Schuster; Annette Reboli; John Wingard; Carola Arndt; John Reinhardt; Susan Hadley; Robert Finberg; Michél Laverdière; John Perfect; Gary Garber; Giuseppe Fioritoni; Eli Anaissie; Jeanette Lee
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

6.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.

Authors:  Johan Maertens; Koen Theunissen; Gregor Verhoef; Johnny Verschakelen; Katrien Lagrou; Eric Verbeken; Alexander Wilmer; Jan Verhaegen; Marc Boogaerts; Johan Van Eldere
Journal:  Clin Infect Dis       Date:  2005-09-29       Impact factor: 9.079

7.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  T J Walsh; R W Finberg; C Arndt; J Hiemenz; C Schwartz; D Bodensteiner; P Pappas; N Seibel; R N Greenberg; S Dummer; M Schuster; J S Holcenberg
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

Review 8.  Current approaches to diagnosis and treatment of invasive aspergillosis.

Authors:  Brahm H Segal; Thomas J Walsh
Journal:  Am J Respir Crit Care Med       Date:  2005-12-30       Impact factor: 21.405

9.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

Authors:  Thomas J Walsh; Hedy Teppler; Gerald R Donowitz; Johan A Maertens; Lindsey R Baden; Anna Dmoszynska; Oliver A Cornely; Michael R Bourque; Robert J Lupinacci; Carole A Sable; Ben E dePauw
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

10.  Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group.

Authors: 
Journal:  Am J Med       Date:  1989-06       Impact factor: 4.965

View more
  2 in total

1.  Risk-adapted strategy for the management of febrile neutropenia in cancer patients.

Authors:  Jean Klastersky; Marianne Paesmans
Journal:  Support Care Cancer       Date:  2007-02-09       Impact factor: 3.603

2.  Clinical feature, image findings and outcome of hepatosplenic candidiasis in patients with acute myeloid leukemia.

Authors:  Hung Chang; Ming-Chung Kuo; Tzung-Chih Tang; Tung-Liang Lin; Jin-Hou Wu
Journal:  Biomed J       Date:  2020-11-18       Impact factor: 7.892

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.